Segall Bryant & Hamill LLC Acquires 140,709 Shares of Celldex Therapeutics, Inc. $CLDX

Segall Bryant & Hamill LLC raised its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 36.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 528,597 shares of the biopharmaceutical company’s stock after purchasing an additional 140,709 shares during the period. Segall Bryant & Hamill LLC’s holdings in Celldex Therapeutics were worth $13,675,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently made changes to their positions in CLDX. Aster Capital Management DIFC Ltd acquired a new stake in Celldex Therapeutics in the 3rd quarter worth approximately $26,000. Nisa Investment Advisors LLC grew its position in shares of Celldex Therapeutics by 171.7% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 881 shares during the period. Wilmington Savings Fund Society FSB purchased a new stake in shares of Celldex Therapeutics in the third quarter valued at approximately $42,000. Russell Investments Group Ltd. increased its holdings in Celldex Therapeutics by 27.6% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 501 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new position in shares of Celldex Therapeutics during the 3rd quarter worth about $63,000.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Barclays boosted their price target on shares of Celldex Therapeutics from $21.00 to $24.00 and gave the stock an “underweight” rating in a research report on Wednesday, December 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Wednesday, January 21st. Stifel Nicolaus reissued a “buy” rating and issued a $68.00 target price (up from $58.00) on shares of Celldex Therapeutics in a research report on Thursday, February 26th. Finally, The Goldman Sachs Group increased their price target on shares of Celldex Therapeutics from $30.00 to $34.00 and gave the stock a “neutral” rating in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Celldex Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.50.

Celldex Therapeutics Stock Performance

NASDAQ CLDX opened at $28.94 on Wednesday. The firm has a market cap of $1.93 billion, a PE ratio of -7.44 and a beta of 1.17. Celldex Therapeutics, Inc. has a one year low of $14.40 and a one year high of $31.31. The firm’s fifty day moving average is $25.80 and its two-hundred day moving average is $25.58.

Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($1.00) by ($0.22). Celldex Therapeutics had a negative return on equity of 41.67% and a negative net margin of 3,446.88%.The firm had revenue of $0.12 million during the quarter, compared to analyst estimates of $1.53 million. Research analysts predict that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.